BAFF:BCMA Assay Service
●
Target
BAFF:BCMA
●
Description
Screening and/or profiling inhibitor compounds against BAFF:BCMA binding in a biochemical assay.
●
Synonyms
BAFF, BLYS, TALL-1, CD257, TNFRSF13C, B-cell activating factor, TNF13b
●
Example Data
*Example only, final data may vary.
Assay Details
●
Assay Format
Chemiluminescent
●
Reference Compounds and IC50
Anti-BCMA Antibody, 0.3 nM
●
Assay Principle
The BAFF:BCMA[Biotinylated] Inhibitor Screening Assay is designed for screening and profiling inhibitors of BAFF:BCMA interaction. The key to this assay is the high sensitivity of detection of biotin-labeled BCMA by streptavidin-HRP. Only a few simple steps on a microtiter plate are required for the assay. First, BAFF is coated on a 96-well plate. Next, BCMA is incubated with BAFF on the plate with or without inhibitors. Finally, the plate is treated with streptavidin-HRP followed by addition of an HRP substrate to produce chemiluminescence, which can be measured using a chemiluminescence reader.
Target Details
●
Protein Family
Immunotherapy
●
UniProt
BAFF: Q9Y275; BCMA: Q02223
●
Background
The TNF family ligand B-cell Activating Factor (BAFF, also known as BLyS, TALL-1 or CD257, encoded by the TNFSF13B gene) is a Type II membrane-bound protein, which can be released as a soluble ligand upon proteolytic processing. This cytokine is a ligand for the receptors Transmembrane Activator and CAML Interactor (TACI, TNFRSF13B), BAFF Receptor (BAFF-R, TNFRSF13C) and B-cell Maturation Antigen (BCMA, TNFRSF17). These interactions promote cell survival and they play a crucial role in B cell development. In particular, BCMA signaling is an important player in the later stages of B cell differentiation, including the survival of long-lived bone marrow plasma cells and likely for the survival of plasmablasts.
Delivery
●
Estimated Turnaround
Two to three weeks following delivery of compounds
●
Results
Extensive report with raw and analyzed data, graphs, and detailed protocols. Includes positive control for inhibition.
